Group 1 - Wuxi City and the National Cancer Center signed a new cooperation agreement to enhance cancer prevention actions and explore early diagnosis and treatment models, aiming to reduce social medical costs and family economic burdens [1] - The launch of the "Yihui Xicheng" new product by Guolian Life Insurance includes innovative drug and device coverage, and the introduction of the "One-click e-compensation" feature to further alleviate medical expenses for the public [1] - The establishment of the Guolian Health Foundation in Wuxi, with an initial fundraising of 30 million yuan, aims to support research projects such as early screening for gastric cancer and the transformation of radiopharmaceuticals [1] Group 2 - Wuxi has been approved for 3 first-class innovative drugs and 8 second and third-class innovative medical devices, supporting 31 medical-engineering integration projects in the past three years [2] - The city has been recognized as one of the top 20 cities in China's biopharmaceutical industry development index for two consecutive years, with its biopharmaceutical cluster approved as a national advanced manufacturing cluster [2] - Wuxi is accelerating the development of the "Wuxi Biopharmaceutical Full Industry Chain Open Innovation Development Implementation Plan" and the "Wuxi High-tech Zone Biopharmaceutical Industry Development Plan (2025-2030)" [2]